Aimmune Therap (AIMT) Stock Price, Forecast & Analysis
USA - NASDAQ:AIMT -
AIMT Key Statistics, Chart & Performance
The current stock price of AIMT is 34.49 null. In the past month the price increased by 0.52%. In the past year, price increased by 37.14%.
AIMT Latest News, Press Relases and Analysis
About AIMT
Company Profile
Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.
Company Info
Aimmune Therap
8000 MARINA BOULEVARD SUITE 300
BRISBANE CA 94005
CEO: Jayson Dallas
Phone: 650-614-5220
Aimmune Therap / AIMT FAQ
What does Aimmune Therap do?
Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.
Can you provide the latest stock price for Aimmune Therap?
The current stock price of AIMT is 34.49 null. The price decreased by -0.29% in the last trading session.
Does Aimmune Therap pay dividends?
AIMT does not pay a dividend.
How is the ChartMill rating for Aimmune Therap?
AIMT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for AIMT stock?
Aimmune Therap (AIMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.33).
AIMT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AIMT. When comparing the yearly performance of all stocks, AIMT is one of the better performing stocks in the market, outperforming 95.58% of all stocks.
AIMT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AIMT. The financial health of AIMT is average, but there are quite some concerns on its profitability.
AIMT Financial Highlights
Over the last trailing twelve months AIMT reported a non-GAAP Earnings per Share(EPS) of -4.33. The EPS decreased by -16.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -49918.09% | ||
| ROA | -78.58% | ||
| ROE | N/A | ||
| Debt/Equity | 0.73 |